Jourdren Guenola, Berveiller Paul, Rousseau Anne
Midwifery Department, Versailles Saint Quentin University, Paris-Saclay University, Montigny-le-Bretonneux, France.
Department of Obstetrics and Gynecology, Poissy-Saint-Germain en Laye Hospital, Poissy, France.
J Matern Fetal Neonatal Med. 2022 Dec;35(25):7629-7639. doi: 10.1080/14767058.2021.1957822. Epub 2021 Aug 25.
Despite the availability guidelines to prevent RhD alloimmunization, severe hemolytic disease of fetus and newborn still occurs in high-income countries. The aim of the study was (1) To assess variations in practices for the prevention of RhD alloimmunization, and (2) to understand midwives' acceptance and appropriation of fetal RhD genotyping.
Descriptive cross-sectional survey of French midwives from September 2017 through January 2018. Participants were asked to complete an internet-based questionnaire that included three clinical vignettes. They were questioned about their practices concerning early pregnancy visit by RhD-negative women, prevention of RhD alloimmunization in women with second-trimester metrorrhagia, and RhD fetal genotyping.
A total of 827 midwives completed the questionnaire. Only 21.1% reported that they practice all the preventive measures recommended in early pregnancy. In a situation at high risk of RhD alloimmunization during pregnancy, 97.2% of midwives would perform immunoprophylaxis. Nearly, all midwives reported providing information about RhD alloimmunization (92.4%) at the beginning of pregnancy, although only 11.3% offered both written and verbal information; at the time of systematic anti-D immunoprophylaxis (28 weeks), 78% provided information, but only 2.7% both verbally and in writing. Finally, only 50.8% of midwives preferred to include RhD fetal genotyping in routine prenatal prophylaxis.
This study showed significant variations in French midwives' practices to prevent RhD alloimmunization. Better dissemination of guidelines is needed to improve both consistent use of these practices and the quality of information delivered to RhD-negative pregnant women.
尽管有预防RhD同种免疫的指南,但高收入国家仍会发生严重的胎儿及新生儿溶血病。本研究的目的是:(1)评估预防RhD同种免疫措施的差异;(2)了解助产士对胎儿RhD基因分型的接受程度和应用情况。
对2017年9月至2018年1月期间的法国助产士进行描述性横断面调查。参与者被要求完成一份基于网络的问卷,其中包括三个临床案例。询问她们关于RhD阴性女性早孕检查、孕中期出血女性预防RhD同种免疫以及RhD胎儿基因分型的相关做法。
共有827名助产士完成了问卷。只有21.1%的人报告说他们实施了早孕时推荐的所有预防措施。在孕期有RhD同种免疫高风险的情况下,97.2%的助产士会进行免疫预防。几乎所有助产士都报告在孕早期提供了关于RhD同种免疫的信息(92.4%),但只有11.3%同时提供了书面和口头信息;在进行系统性抗D免疫预防时(28周),78%的人提供了信息,但只有2.7%同时进行了口头和书面告知。最后,只有50.8%的助产士倾向于将RhD胎儿基因分型纳入常规产前预防。
本研究表明法国助产士在预防RhD同种免疫的做法上存在显著差异。需要更好地传播指南,以提高这些做法的一致应用以及向RhD阴性孕妇提供信息的质量。